FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118670147> ?p ?o ?g. }

• W2118670147 endingPage "201" @default.
• W2118670147 startingPage "199" @default.
• W2118670147 abstract "Pain ManagementVol. 1, No. 3 EditorialFree AccessTargeting ion channel trafficking mechanisms for novel analgesicsArin BhattacharjeeArin BhattacharjeeThe State University of New York at Buffalo, Department of Pharmacology & Toxicology, 102 Farber Hall, Buffalo, NY, 14214, USA. Search for more papers by this authorEmail the corresponding author at ab68@buffalo.eduPublished Online:5 May 2011https://doi.org/10.2217/pmt.11.23AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail In February of this year, the New York Times reported on the increasing number of brazen robberies occurring at pharmacies throughout the USA. One thief in Rockland (ME, USA) brandished a machete and leapt over the pharmacy counter to grab oxycodone. He gulped down some of it even before he fled. In Florida, thousands of doses of oxycodone pills are dispensed in pain clinics, resulting in some calling the highway that leads into Florida, I-75, the ‘Oxy Express’. In 2008, Ohio pharmacists dispensed 4.8 million prescriptions for hydrocodone medications, one for every 2.5 people in the state [101]. Although we have been treating pain effectively for millennia, the need for efficacious, safe but especially nonaddictive analgesics remains strong. We require analgesics that can specifically act on peripheral pain-sensing neurons and not centrally to avert addiction. In this article, I argue that the future of pain research must include the development of compounds that directly target the ion channel trafficking machinery of nociceptors.Analgesics act by reducing the firing properties of neurons within the pain pathway. For treatment of mild pain, nonsteroidal antiflammatory drugs (NSAIDs) are recommended. These agents reduce algogenic substances, such as prostaglandins, which directly affect the firing properties of nociceptive neurons. NSAID use is widespread; however, gastrointestinal and renal toxicities associated with these agents are prevalent, with an estimated 10–20% of NSAID patients experiencing dyspepsia [1]. The development of cyclooxygenase-2 selective inhibitors, which minimize gastrointestinal effects, seemed promising, but their severe cardiovascular toxicities have dramatically restricted their use. Vioxx®, the most famous of the cyclooxygenase-2 inhibitor drug class, had to be removed from the market owing to its toxic effects. For moderate-to-severe pain, moderate opioid agonists, such as hydrocodone, strong opioid agonists, such as oxycodone, or even morphine are used. These agents act on opioid receptors in the CNS, especially on descending pathways originating from the periaqueductal gray matter, to block pain transmission in the dorsal horn of the spinal cord. They can also act presynaptically by inhibiting neurotransmitter release from the central terminations of nociceptors in the spinal cord. Opioids do so via µ-receptors, ultimately affecting potassium and calcium conductances. As opioids act centrally, they also produce sedation, euphoria or dysphoria, nausea and vomiting, and in overdose, deadly respiratory depression.Nonsteroidal antiflammatory drugs and opiods are very good for relieving inflammatory pain states: pain that arises from acute tissue injury or trauma. However, there are limitations to these drugs when pain results from nerve injury. Nerve injury pain, called neuropathic pain, can be caused by nerve compression, spinal cord injury, diabetes, alcoholism, cancer chemotherapy and postherpectic neuralgia. Nerve damage results in the persistent action potential firing of primary nociceptive afferents. The continual input from discharging nociceptors induces synaptic changes in the spinal cord, causing central sensitization. It is important to realize that continual discharging afferents are required for maintenance of central sensitization [2]. Therefore, for neuropathic pain, alternative types of analgesics are required. Antiepileptic drugs such as carbamazepine, phenytoin and valproate are used. These drugs directly target ion channels, particularly sodium channels, to reduce excitability. However, they are antiepileptic drugs acting centrally and, as such, are also associated with many side effects.Are there any similarities between chronic inflammatory pain and neuropathic pain? Both pain states depend on nociceptor hyperexcitability [3–5]. Therefore, developing drugs that act peripherally, targeting ion channels and thereby reducing primary afferent sensitization, is a logical analgesic approach to take to minimize side effects and prevent addiction.Which ion channel(s) should we target? The answer to this question is not so simple. There has been extensive research trying to determine the principle ion channels that are responsible for nociceptor hyperexcitability in animal models of inflammatory and neuropathic pain. Heavy emphasis has been placed on the central role of voltage-dependent sodium channels in primary afferent hyperexcitability. However, recent transgenic animal studies indicate that increased sodium channel activity may not be essential in the pathophysiology of inflammatory and neuropathic pain [6]. Calcium channels, in particular T-type calcium channels, have drawn considerable attention because they are upregulated in neuropathic pain [7], and specific T-type calcium channel antagonists have been tested for their abilities to treat neuropathic pain [8]. However, targeting sodium and calcium channels poses toxicity issues, because many of the same channel subtypes expressed in nociceptors are also expressed in other neuronal and non-neuronal tissues. Potassium channels also offer unique analgesic targets. Potassium currents in nociceptors are also affected by inflammation and neuropathy, and therefore developing potassium channel openers to increase their activity will impact nociceptor hyperexcitability. Potassium channels are far more diverse than sodium and calcium channels, and the unique repertoire of potassium channels that are expressed in nociceptors could be of considerable pharmacological interest [9].From my 11 years of experience studying sodium-activated potassium (KNa) channels, I have found their expression in rats to be the highest in trigeminal and dorsal root ganglion neurons [10,11]. Why sensory neurons express high levels of KNa channels still remains to be fully answered. However, my research team has recently demonstrated that PKA activation results in the internalization of KNa channels from the dorsal root ganglia neuronal membrane and this was associated with hyperexcitability [12]. The most remarkable aspect of these findings is that there is a robust ion channel trafficking capacity in nociceptive neurons: signal activation causes ion channels to move in and out of the nociceptor membrane [12–15]. Ion channel trafficking offers nociceptive neurons a rapid but prolonged method for changing their firing properties. Up until this point, many have assumed that inflammatory mediators modulate nociceptors primarily through phosphorylation-/dephosphorylation-dependent changes in ion channel gating. While this process is important, I would like to highlight that phosphorylation-dependent changes in channel gating are transient. Dorsal root ganglia neuronal hyperexcitability in either neuropathic pain or inflammatory pain occurs in the magnitude of hours, days, weeks or even years. We need to appreciate the long-term regulation of ion channels at the plasma membrane in pain-sensing neurons. This is akin to the understanding of ion channel clustering and trafficking during synaptic plasticity in the CNS. It is within the context of ion channel trafficking that I think efficacious, nontoxic analgesics can be developed. Merely applying channel blockers or channel openers will inevitably lead to adverse side effects. If we can disrupt channel trafficking mechanisms that result from prostaglandin-induced inflammatory signaling for example, we could produce an analgesic-specific effect without the side effects, such as addiction, of current analgesics. Indeed, this may be how the well-tolerated drug gabapentin, which controls the trafficking of calcium channels [16], is efficacious for neuropathic pain.Future research is still required to understand nociceptor hyperexcitability during inflammatory and neuropathic pain signaling; we need to identify the dynamic ion channel processes associated with hyperexcitability. If we can elucidate the molecular underpinnings of nociceptor hyperexcitability, it will lead to better and safer analgesics. Unfortunately, within the USA, the NIH devotes only a fraction of a percentage of its total budget to pain research and, given the recent decline in interest for developing new therapeutics by pharmaceutical companies, it is unclear where the impetus will come for the development of novel channel targeted drugs. Perhaps the Drug Enforcement Agency, with its billion-dollar budget, could devote a portion of its resources to fund research whose sole purpose is to develop nonaddictive analgesics. It may be as cost effective as trying to protect pharmacies from bandits gallivanting down the Oxy Express.Financial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.Bibliography1 Green GA: Understanding NSAIDs: from aspirin to COX-2. Clin. Cornerstone3(5),50–60 (2001).Crossref, Medline, CAS, Google Scholar2 Pitcher GM, Henry JL: Governing role of primary afferent drive in increased excitation of spinal nociceptive neurons in a model of sciatic neuropathy. Exp. Neurol.214,219–228 (2008).Crossref, Medline, Google Scholar3 Reichling DB, Levine JD: Critical role of nociceptor plasticity in chronic pain. Trends Neurosci.32,611–618 (2009).Crossref, Medline, CAS, Google Scholar4 Xu J, Brennan TJ: Guarding pain and spontaneous activity of nociceptors after skin versus skin plus deep tissue incision. Anesthesiology112,153–164 (2010).Crossref, Medline, Google Scholar5 Wu G, Ringkamp M, Murinson BB et al.: Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. J. Neurosci.22,7746–7753 (2002).Crossref, Medline, CAS, Google Scholar6 Krafte DS, Bannon AW: Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr. Opin. Pharmacol.8,50–56 (2008).Crossref, Medline, CAS, Google Scholar7 Jagodic MM, Pathirathna S, Joksovic PM et al.: Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J. Neurophysiol.99,3151–3156 (2008).Crossref, Medline, CAS, Google Scholar8 Todorovic SM, Jevtovic-Todorovic V: T-type voltage-gated calcium channels as targets for the development of novel pain therapies. Br. J. Pharmacol. DOI: 10.1111/j.1476-5381.2011.01256.x (2011) (Epub ahead of print).Medline, Google Scholar9 Ocana M, Cendan CM, Cobos EJ, Entrena JM, Baeyens JM: Potassium channels and pain: present realities and future opportunities. Eur. J. Pharmacol.500,203–219 (2004).Crossref, Medline, CAS, Google Scholar10 Bhattacharjee A, Gan L, Kaczmarek LK: Localization of the Slack potassium channel in the rat central nervous system. J. Comp. Neurol.454,241–254 (2002).Crossref, Medline, CAS, Google Scholar11 Tamsett TJ, Picchione KE, Bhattacharjee AL: NAD+ Activates KNa channels in dorsal root ganglion neurons. J. Neurosci.29,5127–5134 (2009).Crossref, Medline, CAS, Google Scholar12 Nuwer MO, Picchione KE, Bhattacharjee A: PKA-induced internalization of Slack KNa channels produces dorsal root ganglion neuron hyperexcitability. J. Neurosci.30,14165–14172 (2010).Crossref, Medline, CAS, Google Scholar13 Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ: p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron36,57–68 (2002).Crossref, Medline, CAS, Google Scholar14 Zhang X, Huang J, McNaughton PA: NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J.24,4211–4223 (2005).Crossref, Medline, CAS, Google Scholar15 Fabbretti E, D’Arco M, Fabbro A, Simonetti M, Nistri A, Giniatullin R: Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide. J. Neurosci.26,6163–6171 (2006).Crossref, Medline, CAS, Google Scholar16 Bauer CS, Tran-Van-Minh A, Kadurin I, Dolphin AC: A new look at calcium channel α2δ subunits. Curr. Opin. Neurobiol.20,563–571 (2010).Crossref, Medline, CAS, Google Scholar101 Illegal prescription-drug trade now epidemic www.dispatch.com/live/content/local_news/stories/2010/02/07/OXYCONTIN.ART_ART_02-07-10_A1_HGGH7K4.htmlGoogle ScholarFiguresReferencesRelatedDetails Vol. 1, No. 3 Follow us on social media for the latest updates Metrics Downloaded 280 times History Published online 5 May 2011 Published in print May 2011 Information© Future Medicine LtdFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2118670147 created "2016-06-24" @default.
• W2118670147 creator A5019487275 @default.
• W2118670147 date "2011-05-01" @default.
• W2118670147 modified "2023-10-16" @default.
• W2118670147 title "Targeting ion channel trafficking mechanisms for novel analgesics" @default.
• W2118670147 cites W1963857381 @default.
• W2118670147 cites W1965108173 @default.
• W2118670147 cites W1991063399 @default.
• W2118670147 cites W1996906033 @default.
• W2118670147 cites W2027905035 @default.
• W2118670147 cites W2040642697 @default.
• W2118670147 cites W2041815912 @default.
• W2118670147 cites W2053989438 @default.
• W2118670147 cites W2074188832 @default.
• W2118670147 cites W2077239893 @default.
• W2118670147 cites W2080410552 @default.
• W2118670147 cites W2085408699 @default.
• W2118670147 cites W2086714349 @default.
• W2118670147 cites W2107595042 @default.
• W2118670147 cites W2137445147 @default.
• W2118670147 doi "https://doi.org/10.2217/pmt.11.23" @default.
• W2118670147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24646383" @default.
• W2118670147 hasPublicationYear "2011" @default.
• W2118670147 type Work @default.
• W2118670147 sameAs 2118670147 @default.
• W2118670147 citedByCount "0" @default.
• W2118670147 crossrefType "journal-article" @default.
• W2118670147 hasAuthorship W2118670147A5019487275 @default.
• W2118670147 hasConcept C126322002 @default.
• W2118670147 hasConcept C169760540 @default.
• W2118670147 hasConcept C170493617 @default.
• W2118670147 hasConcept C50254741 @default.
• W2118670147 hasConcept C60644358 @default.
• W2118670147 hasConcept C70721500 @default.
• W2118670147 hasConcept C71924100 @default.
• W2118670147 hasConcept C86803240 @default.
• W2118670147 hasConcept C98274493 @default.
• W2118670147 hasConceptScore W2118670147C126322002 @default.
• W2118670147 hasConceptScore W2118670147C169760540 @default.
• W2118670147 hasConceptScore W2118670147C170493617 @default.
• W2118670147 hasConceptScore W2118670147C50254741 @default.
• W2118670147 hasConceptScore W2118670147C60644358 @default.
• W2118670147 hasConceptScore W2118670147C70721500 @default.
• W2118670147 hasConceptScore W2118670147C71924100 @default.
• W2118670147 hasConceptScore W2118670147C86803240 @default.
• W2118670147 hasConceptScore W2118670147C98274493 @default.
• W2118670147 hasIssue "3" @default.
• W2118670147 hasLocation W21186701471 @default.
• W2118670147 hasLocation W21186701472 @default.
• W2118670147 hasOpenAccess W2118670147 @default.
• W2118670147 hasPrimaryLocation W21186701471 @default.
• W2118670147 hasRelatedWork W122890370 @default.
• W2118670147 hasRelatedWork W1985229058 @default.
• W2118670147 hasRelatedWork W2043019576 @default.
• W2118670147 hasRelatedWork W2049223395 @default.
• W2118670147 hasRelatedWork W2128495829 @default.
• W2118670147 hasRelatedWork W2227238226 @default.
• W2118670147 hasRelatedWork W2915911434 @default.
• W2118670147 hasRelatedWork W383346514 @default.
• W2118670147 hasRelatedWork W4212974175 @default.
• W2118670147 hasRelatedWork W4238035952 @default.
• W2118670147 hasVolume "1" @default.
• W2118670147 isParatext "false" @default.
• W2118670147 isRetracted "false" @default.
• W2118670147 magId "2118670147" @default.
• W2118670147 workType "article" @default.